Molecular staging of gynecological cancer: What is the future?

Pratibha S. Binder, Jaime Prat, David G. Mutch

Research output: Contribution to journalArticlepeer-review

8 Scopus citations


The purpose of cancer staging is to classify cancers into prognostic groups and to allow for comparison of treatment results and survival between patients and institutions. Staging for gynecologic cancers is based on extent of disease and metastasis, which was historically determined by physical examination and is now based on surgical and histologic examination of tumor specimens. Although the extent of disease is currently considered the most important predictor of recurrence and survival, current staging does not include molecular features that are associated with tumor aggressiveness, response to therapy, and prognosis. This review focuses on genomic and proteomic features of gynecologic cancers and the future of biomarkers in staging classification.

Original languageEnglish
Article number1469
Pages (from-to)776-789
Number of pages14
JournalBest Practice and Research: Clinical Obstetrics and Gynaecology
Issue number6
StatePublished - Aug 1 2015


  • biomarker
  • gynecologic cancer
  • molecular classification
  • prognosis
  • staging


Dive into the research topics of 'Molecular staging of gynecological cancer: What is the future?'. Together they form a unique fingerprint.

Cite this